RT Journal Article
SR Electronic
T1 Pharmaceutical Development of a Parenteral Lyophilised Dosage Form for the Novel Anticancer Agent C1311
JF PDA Journal of Pharmaceutical Science and Technology
JO PDA J Pharm Sci Technol
FD Parenteral Drug Association (PDA)
SP 285
OP 297
VO 59
IS 5
A1 Monique W. J. Den Brok
A1 Bastiaan Nuijen
A1 J. Jantina Kettenes-Van Den Bosch
A1 M. J. Van Steenbergen
A1 Josie N. Buluran
A1 Michael D. Harvey
A1 Charles K. Grieshaber
A1 Jos H. Beijnen
YR 2005
UL http://journal.pda.org/content/59/5/285.abstract
AB C1311 (5-[[2-(diethylamino)ethyl]amino]-8-hydroxyimidazo [4,5,1-de]-acridin-6-one-dihydrochloride trihydrate) is the lead compound from the group of imidazoacridinones, a novel group of rationally designed anticancer agents. C1311 shows significant cytotoxic activity in vitro and in vivo toward a range of colon tumours. The aim of the present study is to develop a sterile and stable, injectable pharmaceutical product for C1311 to be used in phase I clinical trials. C1311 drug substance was structurally and analytically characterised by chromatographic, spectrometric, and diffraction techniques. C1311 was freely soluble in water, and its stability was investigated in several liquid and lyophilised formulations with or without the use of buffering, tonicity, and bulking agents. The final product, containing 100 mg/vial C1311 (as anhydrous free base), was stable for at least 3 months under accelerated storage conditions and at the designated long-term storage condition of 5 ± 3 °C in the dark. The drug is currently used in phase I clinical trials.